Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Multiple Cancer Types
The purpose of this study is to find out whether the study drug, LY3537982, is safe and
effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must
have already received or were not able to tolerate the standard of care, except for specific
groups who have not had cancer treatment. The study will last up to approximately 4 years.
effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must
have already received or were not able to tolerate the standard of care, except for specific
groups who have not had cancer treatment. The study will last up to approximately 4 years.
Colon,
Gastrointestinal,
Lung,
Miscellaneous,
Non Small Cell,
Phase I,
Rectal
I
Iams, Wade
NCT04956640
VICCTHOP2155
